OSR Holdings Jumps 27% on Vaximm’s $815M Licensing Deal with BCM Europe
OSR Holdings, Inc. (OSRH) surged 27% intraday after its subsidiary Vaximm AG announced a strategic licensing agreement with BCM Europe AG for cancer immunotherapy drug VXM01. The non-binding term sheet outlines a potential $20M upfront payment and $815M in milestones, triggering investor Optimism about OSRH's biotech portfolio.
Market reaction was immediate, with OSRH stock outperforming broader indices. The six-month exclusivity window allows due diligence for a definitive agreement, positioning Vaximm for global commercialization. Biotech analysts note the deal validates OSRH's investment thesis in novel immunotherapies.